Hydroxychloroquine Fails To Help Hospitalized Coronavirus Patients In Us Funded Study

Sarilumab, another IL-6 receptor antagonist, is currently FDA-approved for arthritis rheumatoid. Sarilumab has been used in open-label cohort studies for the management of severe COVID-19 and has undergone analysis in unpublished RCTs for modest and severe COVID-19 [92-96]. Organized review and horizon scan of the literature identified 2030 sources which 48 informed the evidence foundation… Continue reading Hydroxychloroquine Fails To Help Hospitalized Coronavirus Patients In Us Funded Study